Evidence map›Paper›PMID 39348783›Full record

ArticleOral oncology2024

Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.

Katherine Keefe, Hilary C McCrary, Mei Wei, Bayarmaa Mark, Sarah Drejet, Richard B Cannon, Luke O Buchmann, Jason P Hunt, Mark Dodson, Vikrant Deshmukh and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katherine KeefeDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Hilary C McCraryDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Mei WeiDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Bayarmaa MarkDepartment of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Sarah DrejetDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Richard B CannonDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Luke O BuchmannDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Jason P HuntDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Mark DodsonIntermountain Healthcare, Salt Lake City, UT.
Vikrant DeshmukhUniversity of Utah Health Sciences Center, Salt Lake City, UT.
Michael NewmanUniversity of Utah Health Sciences Center, Salt Lake City, UT.
Marcus M MonroeDepartment of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT.
Mia HashibeDepartment of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Sharing statewide health data for genetic research (1 R01 RR021746-01A1)R01RR021746 · NCRR · UNIVERSITY OF UTAH · PI MINEAU, GERALDINE P · 2007 to 2009
$770k
Population-based Cohort of Endometrial Cancer Survivors in UtahR21CA185811 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2015 to 2016
$356k
Epidemiology of testicular cancer in the Utah populationR03CA159357 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2011 to 2012
$150k
NCI NIH HHS P30 CA042014NCI NIH HHS R03 CA159357NCI NIH HHS R21 CA185811NCRR NIH HHS R01 RR021746
6 · The paper itself

Abstract

backgroundIn the United States, approximately 63,000 Americans develop head and neck cancer (HNC) annually. Our study aims were to investigate cardiovascular complications and risk factors for development of CVD among HNC survivors.

methodsUtilizing the Utah Populations Database, a total of 1,901 HNC patients diagnosed and 7,796 birth year, sex, and birth state matched individuals from the general population were identified. Multivariate Cox proportional hazard models were used.

resultsWithin the first two years after cancer diagnosis, HNC survivors had a higher likelihood of developing cardiovascular disease (CVD). High Charleston Comorbidity Index (CCI) score at baseline (Hazard Ratio (HR) 1.67, 95 % 1.28-2.17), stage II and IV disease (HR 1.80, 95 % 1.29-2.51), age >=65 years old (HR 2.31, 95 % 1.85-2.88), chemotherapy (HR 1.47, 95 % 1.15-1.88) were associated with increased CVD risk.

conclusionsCompared to the general population, HNC survivors were more likely to develop cardiovascular diseases, particularly if they had the following risk factors: older age, stage II or IV cancer, high baseline CCI score, and chemotherapy were risk factors for development of CVD.

Indexed as

Cancer SurvivorsCardiovascular DiseasesHead and Neck NeoplasmsAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedProportional Hazards ModelsRisk FactorsUtahCardiac dysrhythmiasCardiomyopathyCardiovascular diseaseComorbiditiesConduction disordersCoronary atherosclerosisHead and neck cancerHeart valve diseaseRisk factors

Identifiers

PMID39348783
PMCPMC12662656

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.